These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 2597313

  • 1. Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar.
    Dostert P, Strolin Benedetti M, Dordain G, Vernay D.
    J Neural Transm Park Dis Dement Sect; 1989; 1(4):269-78. PubMed ID: 2597313
    [Abstract] [Full Text] [Related]

  • 2. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO, von Kummer R, Eckert W, Weicker H.
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [Abstract] [Full Text] [Related]

  • 3. Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects.
    Dostert P, Benedetti MS, Bellotti V, Allievi C, Dordain G.
    J Neural Transm Gen Sect; 1990 Feb; 81(3):215-23. PubMed ID: 2397085
    [Abstract] [Full Text] [Related]

  • 4. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A, Giovannini P, Parati E, Novelli A, Caraceni T, Müller EE.
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [Abstract] [Full Text] [Related]

  • 5. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
    Chouza C, Romero S, de Medina O, Aljanati R, Scarmelli A, Caamano JL, Gonzales Panizza V.
    Eur Neurol; 1987 Dec; 27 Suppl 1():59-67. PubMed ID: 3428309
    [Abstract] [Full Text] [Related]

  • 6. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
    Jensen NO, Dupont E, Hansen E, Mikkelsen B, Mikkelsen BO.
    Eur Neurol; 1987 Dec; 27 Suppl 1():68-72. PubMed ID: 3428310
    [Abstract] [Full Text] [Related]

  • 7. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD.
    Eur Neurol; 1987 Dec; 27 Suppl 1():54-8. PubMed ID: 3322837
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD.
    Adv Neurol; 1987 Dec; 45():493-6. PubMed ID: 3548262
    [No Abstract] [Full Text] [Related]

  • 10. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G, Tesei S, Ferrante C, Cossutta E, Zecchinelli A, Scarlato G.
    Mov Disord; 1988 Dec; 3(1):37-45. PubMed ID: 3050471
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE.
    Eur Neurol; 1987 Dec; 27 Suppl 1():9-20. PubMed ID: 3123242
    [Abstract] [Full Text] [Related]

  • 12. Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
    Nordera GP, Lorizio A, Lion P, Durisotti C, D'Andrea G, Ferro-Milone F.
    Eur Neurol; 1987 Dec; 27 Suppl 1():76-80. PubMed ID: 3322839
    [Abstract] [Full Text] [Related]

  • 13. Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
    Rinne UK.
    Eur Neurol; 1987 Dec; 27 Suppl 1():120-5. PubMed ID: 3428305
    [Abstract] [Full Text] [Related]

  • 14. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
    Birkmayer W, Birkmayer GD.
    J Neural Transm Suppl; 1986 Dec; 22():219-25. PubMed ID: 3097256
    [Abstract] [Full Text] [Related]

  • 15. Madopar HBS. International workshop on the 'on-off-phenomenon in Parkinson's disease. New possibilities for its management. Agno, November 14-16, 1985.
    Eur Neurol; 1987 Dec; 27 Suppl 1():1-142. PubMed ID: 3428304
    [No Abstract] [Full Text] [Related]

  • 16. Open clinical study of Madopar HBS.
    Ludin HP.
    Eur Neurol; 1987 Dec; 27 Suppl 1():73-5. PubMed ID: 3322838
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Madopar HBS and the decompensated phase of Parkinson disease.
    Caraceni T, Nordera N, Lamperti E, Lorizio A.
    Ital J Neurol Sci; 1989 Aug; 10(4):407-14. PubMed ID: 2793413
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Combined (surgical and drug) therapy of parkinsonism].
    Kandel' EI, Iadgarov IS.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984 Aug; 84(8):1157-61. PubMed ID: 6388198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.